Prognostic Significance of Prostate-Specific Antigen Persistence after Radical Prostatectomy: A Systematic Review and Meta-Analysis

• Published in: Cancers Vol. 13; no. 5; p. 948
• Main Authors: Kimura, Shoji, Urabe, Fumihiko, Sasaki, Hiroshi, Kimura, Takahiro, Miki, Kenta, Egawa, Shin
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 24.02.2021; MDPI
• Subjects: Bias; Decision making; Laparoscopy; Lymphatic system; Meta-analysis; Mortality; nodal involvement; Prostate cancer; Prostate-specific antigen; Prostatectomy; PSA persistence; recurrence; Surgery; Systematic Review; United States > US; recurrence; meta-analysis; prostate cancer; PSA persistence; nodal involvement
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers13050948

We performed a systematic review and meta-analysis to assess the prognostic value of prostate-specific antigen (PSA) persistence 4-8 weeks after radical prostatectomy (RP) in patients with prostate cancer, using studies from Medline, Scopus, and Cochrane Library, on 10 October 2020. Studies were eligible if they compared patients with postoperative PSA persistence 4-8 weeks after RP to those without such persistence to assess the value of PSA persistence in prognosticating biochemical recurrence (BCR), disease recurrence, cancer-specific mortality (CSM), and overall mortality (OM) by multivariable analysis. Our review and analysis included nine studies published between 2008 and 2019 with 14,455 patients. Of those studies, 12.0% showed postoperative PSA persistence. PSA persistence was associated with BCR (HR: 4.44, 95% CI: 2.84-6.93), disease recurrence (HR: 3.43, 95% CI: 1.62-7.25), and CSM (HR: 2.32, 95% CI: 1.83-2.95). We omitted meta-analysis on the association of PSA persistence with OM due to an insufficient number of studies. PSA persistence was associated with disease recurrence in a sub-group of patients with pathological nodal involvement (HR: 5.90, 95% CI: 3.76-9.24). Understanding detection of PSA persistence at 4-8 weeks after RP might be useful for patient counseling, follow-up scheduling, and clinical decision-making regarding adjuvant therapies.